Xenobiotic Biotransformation – How the Body Processes Foreign Substances

What Is Xenobiotic Biotransformation?

Xenobiotic biotransformation refers to the enzymatic conversion of foreign chemical substances – called xenobiotics (from Greek xenos = foreign, bios = life) – within the body. Xenobiotics include drugs, environmental pollutants, pesticides, industrial chemicals, and certain food components that are not part of the body´s normal metabolism.

The primary goal of biotransformation is to convert lipophilic (fat-soluble) compounds into hydrophilic (water-soluble) metabolites that can be excreted via the kidneys or bile. Without this process, many substances would accumulate in fatty tissues and exert toxic effects.

Phases of Biotransformation

Xenobiotic biotransformation is classically divided into three phases:

Phase I – Functionalization Reactions

In the first phase, xenobiotics are chemically modified through oxidation, reduction, or hydrolysis. The most important enzyme system involved is the cytochrome P450 (CYP) system, a family of monooxygenases predominantly located in the liver. These reactions introduce or unmask reactive functional groups (e.g., hydroxyl groups) that prepare the molecule for the next phase. In some cases, reactive intermediates formed during Phase I are more toxic than the parent compound – a phenomenon known as metabolic activation.

Phase II – Conjugation Reactions

In the second phase, the reactive groups generated in Phase I are coupled (conjugated) with endogenous molecules such as glucuronic acid, sulfate, glutathione, or glycine. The resulting conjugates are generally more water-soluble, less toxic, and more readily excreted. Key enzymes in this phase include UDP-glucuronosyltransferases (UGT), sulfotransferases, and glutathione S-transferases.

Phase III – Transport Reactions

The third phase involves the active transport of conjugated metabolites out of cells into bile or blood, from where they are excreted renally or via the biliary route. Important transporters include members of the ABC transporter family (e.g., P-glycoprotein, MRP2).

Clinical Significance

Xenobiotic biotransformation has far-reaching clinical implications:

• Drug-drug interactions: Many drugs are metabolized by the same CYP enzymes. Inhibitors or inducers of these enzymes can significantly alter the efficacy and toxicity of co-administered medications.
• Pharmacogenetics: Genetic variants (polymorphisms) in biotransformation enzymes give rise to different metabolizer phenotypes (e.g., poor vs. ultrarapid metabolizers), directly influencing individual drug response.
• Toxicology: Some environmental toxins and carcinogens are converted into their toxic or mutagenic form only after biotransformation – for example, benzo[a]pyrene from cigarette smoke.
• Liver function: In patients with impaired liver function (e.g., liver cirrhosis), biotransformation capacity is reduced, leading to drug accumulation and increased risk of toxicity.

Factors Influencing Biotransformation

The efficiency of xenobiotic biotransformation is affected by numerous factors:

• Age: Neonates and elderly individuals have reduced enzyme activity and metabolic capacity.
• Genetics: Polymorphisms in CYP genes (e.g., CYP2D6, CYP2C19) determine individual metabolizer status.
• Diet: Certain dietary components, such as furanocoumarins in grapefruit juice, inhibit CYP3A4 and can amplify drug effects.
• Comorbidities: Hepatic and renal diseases reduce both biotransformation and excretion capacity.
• Drugs and environmental agents: Enzyme inducers (e.g., rifampicin) or inhibitors (e.g., ketoconazole) alter the rate of xenobiotic metabolism.

References

1. Klaassen CD (ed.): Casarett and Doull's Toxicology – The Basic Science of Poisons. 9th edition. McGraw-Hill Education, 2019.
2. Brunton LL, Hilal-Dandan R, Knollmann BC (eds.): Goodman and Gilman's The Pharmacological Basis of Therapeutics. 13th edition. McGraw-Hill Education, 2017.
3. Zanger UM, Schwab M: Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology and Therapeutics. 2013;138(1):103–141. PubMed PMID: 23333322.